Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

275
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
275
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

477
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
477
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

6.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

341
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
341
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

656
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
656
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

432
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
432

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Satiety to Substance Use: Neural Mechanisms of GLP-1 Signaling in Appetite and Reward.

Biological psychiatry·2026
Same author

Glucagon-like peptide-1 signaling in learning and memory: evidence, mechanisms, and therapeutic implications.

Biological psychiatry·2026
Same author

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same author

Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody.

Kidney international·2026
Same author

GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory.

Comprehensive Physiology·2026
Same author

GIPR signaling modulates PYY-induced hypophagia and malaise in rodents.

Molecular metabolism·2026

Related Experiment Video

Updated: Sep 24, 2025

Gastrointestinal Motility Monitor GIMM
08:15

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

31.0K

GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior.

Ricardo J Samms1, Richard Cosgrove1, Brandy M Snider1

  • 1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN.

Diabetes
|May 2, 2022
PubMed
Summary

Glucose-dependent insulinotropic polypeptide (GIP) receptor agonism alleviates nausea-like behaviors induced by peptide YY (PYY) in mice. This finding suggests GIP-based therapies could improve the tolerability of weight loss medications.

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.0K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.3K

Related Experiment Videos

Last Updated: Sep 24, 2025

Gastrointestinal Motility Monitor GIMM
08:15

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

31.0K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.0K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • Nausea and emesis are significant limitations for obesity medications, impacting patient adherence and therapeutic outcomes.
  • Peptide YY (PYY) receptor agonists, while effective for weight loss, frequently cause nausea and vomiting.
  • Improving the tolerability of weight loss agents is crucial for maximizing their clinical benefit.

Purpose of the Study:

  • To investigate whether glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism can mitigate nausea-like behaviors induced by PYY.
  • To explore the neural mechanisms underlying the interaction between GIPR and PYY signaling in the context of nausea.

Main Methods:

  • Administration of GIPR and PYY agonists in mice to assess conditioned taste avoidance (CTA) and hypophagia.
  • Analysis of GIP receptor (Gipr) and PYY receptor (Npy2r) expression in the area postrema (AP).
  • Measurement of neuronal activation using cFos expression in the AP and parabrachial nucleus (PBN) following drug administration.
  • Whole-brain cFos analyses to map PYY-induced neural activity changes and the effect of GIPR agonism.

Main Results:

  • Central and peripheral GIPR agonism significantly reduced PYY-induced CTA without altering PYY-mediated hypophagia.
  • Gipr and Npy2r were co-expressed on neurons within the AP, a key area for emetic signaling.
  • GIPR agonism decreased PYY-induced neuronal activation in the PBN, a critical relay for aversive signals.
  • Peripheral GIPR agonist administration activated neurons in the AP.

Conclusions:

  • GIPR agonism effectively reduces PYY-induced nausea-like behaviors in mice, suggesting a potential therapeutic strategy.
  • The findings reveal a novel mechanism involving GIPR modulation of PYY signaling in the brainstem (AP and PBN).
  • GIP-based therapeutics may offer a way to enhance the tolerability of current and future weight loss agents.